Oasmia Pharma Revenue, Profits - OASM Quarterly Income Statement

Add to My Stocks
$2.56 $0.19 (6.91%) OASM stock closing price Sep 20, 2018 (Closing)

OASM stock valuation based on fundamental analysis involves checking and analyzing financial statements and not just the Oasmia Pharma stock price. An income statement is one of the three key financial statements furnished by a company, the other two being the balance sheet and the cashflow statement. The income statement is generated for a specific period of time, typically a year or a quarter. The revenue decrease to $- for 2019 Q1 impacts the OASM stock. Investors typically check year over year or quarter over quarter revenue growth. One also needs to look at Oasmia Pharma assets, operating expenses and Oasmia Pharma free cash flow. The Oasmia Pharma profit and loss statement shows revenue of $- for 2019 Q1. Revenue has decreased by 0 QoQ for OASM stock.

View and download details of revenue and profits for Oasmia Pharma for latest & last 40 quarters.
show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is May - Apr2019 Q12018 Q42018 Q32018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q4
Oasmia Pharma Revenues or Net Sales
----------
Cost Of Goods Sold (COGS)----------
Oasmia Pharma Gross Profit
-0.09M-0.1M-0.05M--0.03M-0.18M-0.07M-0.05M-0.02M-
Research & Development Expense----------
Selling General & Admin Expense1.39M1.76M1.37M1.33M1.66M2.23M1.83M2.49M1.9M1.99M
Income Before Depreciation Depletion Amortization-1.49M-1.74M-1.42M-1.23M-1.7M-2.39M-1.9M-2.55M-1.93M-1.99M
Depreciation Depletion Amortization----------
Non Operating Income1.42M1.54M1.46M1.36M1.48M1.65M1.8M1.48M1.86M1.95M
Interest Expense----------
Oasmia Pharma Pretax Income
-3.59M-3.92M-3.52M-3.1M-3.69M-4.66M-4.38M-4.8M-4.49M-4.38M
Provision for Income Taxes----------
MinorityInterest----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-3.59M-3.92M-3.52M-3.1M-3.93M-4.71M-4.39M-4.81M-4.42M-3.97M
Extraordinary Items & Discontinued Operations----------
Oasmia Pharma Profit/ Loss (Net Income)
-3.59M-3.93M-3.52M-3.1M-3.93M-4.71M-4.39M-4.81M-4.42M-3.97M
Average Shares used to compute Diluted EPS57.58M58.8M60.67M59.74M45.56M39.84M39.42M35.74M35.74M35.24M
Average Shares used to compute Basic EPS57.58M58.8M60.67M59.74M45.56M39.84M39.68M35.74M35.74M35.24M
Income Before Nonrecurring Items-3.59M-3.9M-3.52M-3.1M-3.93M-4.71M-4.39M-4.81M-4.42M-3.97M
Income from Nonrecurring Items----------
Oasmia Pharma Earnings Per Share Basic Net
-0.06-0.07-0.06-0.05-0.09-0.12-0.11-0.14-0.12-0.11
Oasmia Pharma Earnings Per Share Diluted Net
-0.06-0.07-0.06-0.05-0.09-0.12-0.11-0.14-0.12-0.11
EPS Diluted Before Nonrecurring Items-0.06-0.07-0.06-0.05-0.09-0.12-0.11-0.14-0.12-0.11
Preferred Dividends Acc Pd----------
Dividends Common0.000.000.00-------
Dividend Per Share Common0.000.000.000.000.020.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Oasmia Pharma stock analysis involves checking at least a few of the important things like:

  • Revenue: This is the inflow that is generated from the sale of goods or services and is $- for this quarter of 2019 Q1. Our Oasmia Pharma revenue chart gives a clear visual representation of how the topline or sales growth has been. Investors often invest only in those companies where the revenue is growing at a steady rate.
  • Bottom line: Most businesses like Oasmia Pharma try to grow their profits by growing their topline and by increasing their operating efficiency. A healthy bottom line growth implies a good investment.

The income statement is also called statement of revenue and expense. The OASM financials along with Oasmia Pharma historical stock prices provide a lot of details about the firm.

Oasmia Pharma Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
359.52
Dividend Yield
0%

Other Income Statements - Oasmia Pharmaceutical AB - American Depositary Shares Industry Peers

CTI BioPharma income statement, MOLECULAR TEMPL income statement, PROCESSA PHARMA income statement